[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

613.P1.50 Acute Myeloid Leukemia - Biology and Pathophysiology Poster I

Oral and Poster Abstracts
Poster Session
Saturday, December 5, 2009: 5:30 PM-7:30 PM
Hall E (Ernest N. Morial Convention Center)
Pathophysiology of Patients Over the Age of 65 with Acute Myeloid Leukemia (AML)

Henna Malik, M.D.1*, Lucas Wong, MD1, Sarju Waghela, MD1*, Lisa Go2*, William Koss3*, Juhee Song4*, Pandora Ashley5* and Takeshi Wajima, MD, PhD1

1Division of Hemotology/Oncology, Scott and White Memorial Hospital and Clinic, Temple, TX
2Carl R. Darnall Army Medical Center, Fort Hood, TX
3Anatomic & Clinical Pathology, Scott and White Memorial Hospital and Clinic, Temple, TX
4Biostatistics Department, Scott & White Memorial Hospital, Temple, TX
5Tumor Registry, Scott & White Memorial Hospital, Temple, TX

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML)

Gloria Mattiuzzi, MD1, Jorge Cortes, MD1, Deborah McCue, PhDP2*, B. Nebiyou Bekele, PhD3*, Lianchun Xiao3*, Gautam Borthakur, MD1 and Hagop Kantarjian, MD1

1Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
2Clinical Pharmacy Services, U.T. M.D. Anderson Cancer Center, Houston, TX
3Department of Biostatistics, U.T. M.D. Anderson Cancer Center, Houston, TX

The Receptor Tyrosine Kinase RON Is Constitutively Activated in Acute Myeloid Leukemia and May Represent a New Therapeutic Target

Camille Fialin1*, Veronique De Mas1*, Stephane Manenti1*, Bernard Payrastre, PhD2*, Serge Roche3* and Christian Recher4*

1Departement d'Oncogenese, Signalisation et Innovation therapeutique, Inserm U563, Toulouse, France
2Centre de Physiopathologie de Toulouse Purpan et Université Paul Sabatier, Département d'Oncogenèse, Signalisation et Innovation, Inserm U563, Toulouse
3Centre de recherche de biochimie macromoléculaire, CNRS UMR5237,, Montpellier, France
4Service d'Hematologie, CHU de Toulouse, Toulouse, France

Mutation and Single-Nucleotide Polymorphism (rs16754) in Wilms Tumor-1 Gene Are Independent Prognostic Factors in Acute Myeloid Leukemia

Wanlong Ma1*, Hagop Kantarjian, MD2, XI Zhang1*, Xiuqiang Wang1*, Zhong Zhang, MD, PhD1*, Chen-Hsiung Yeh1*, Anthony Sferruzza, PhD1, Susan O'Brien3* and Maher Albitar, M.D.1*

1Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
2Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
3Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Low CLIP Expression On Leukemic Blasts From AML Patients Is Essential for the Generation of Effective CD4+ T Cell Responses

Marvin M. van Luijn1*, Martine E.D. Chamuleau, MD, PhD1, James A. Thompson2*, Suzanne Ostrand-Rosenberg, PhD2*, Theresia M. Westers, PhD1*, Yuri Souwer3*, Gert J. Ossenkoppele, MD, PhD1, S. Marieke van Ham, PhD3* and Arjan A. van de Loosdrecht, MD, PhD1

1Department of Hematology, VU University Medical Center, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands
2Department of Biological Sciences, University of Maryland, Baltimore, MD
3Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles

Hendrik JM de Jonge1*, Peter Valk, PhD2*, Kim R Kampen1*, Arja ter Elst, PhD1*, Gertjan Kaspers, MD, PhD3, Jacqueline Cloos, PhD3*, C. Michel Zwaan, MD, PhD4, Marry M van den Heuvel-Eibrink, MD, PhD4*, Willem A. Kamps, MD, PhD1, Ruud Delwel, PhD2, Bob Lowenberg, MD, PhD2 and Eveline S de Bont, MD, PhD1*

1Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
2Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
3Division of Pediatric Oncology / Hematology, VU University Medical Center, Amsterdam, Netherlands
4Department of Pediatric Hematology/Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands

Continuous Decrease of Overall Survival in Patients > 30 Years of Age with Acute Myelogenous Leukemia

Utz O. Krug, MD1*, Wolfgang Berdel, MD2, Susanne Amler3*, Maria C. Sauerland, PhD3*, Bernhard Wörmann, MD4*, Wolfgang Hiddemann, MD5* and Thomas Buchner, MD1

1Dept. of Internal Medicine, Hematology/Oncology, University of Münster, Münster, Germany
2Department of Medicine (Hematology/Oncology), University of Muenster, Muenster, Germany
3Dept. of Medical Informatics and Biomathematics, Universität Münster, Münster, Germany
4Municipal Medical Center, Braunschweig, Germany
5Department of Medicine III, Klinikum Grosshadern, LMU, Munich, Germany

NPM1 Mutations Have a High Impact On the Development of Secondary AML

Susanne Schnittger, PHD, Tamara Weiss*, Frank Dicker, PHD, Jana Sundermann*, Wolfgang Kern, MD, Claudia Haferlach, MD and Torsten Haferlach, MD

MLL Munich Leukemia Laboratory, Munich, Germany

Impaired S Phase Arrest in AML Cells with a FLT3-ITD Treated with Clofarabine Allows Prolonged Drug exposure  to Reverse the Chemoresistant Phenotype

Claire Seedhouse, PhD1*, Martin Grundy, BSc1*, Shili Shang, MD, MSc1*, John Ronan, CSci, FIBMS2*, Heather Pimblett1*, Nigel H. Russell, MD3 and Monica Pallis, PhD2*

1Academic Haematology, University of Nottingham, Nottingham, United Kingdom
2Academic Haematology, Nottingham University Hospitals, Nottingham, United Kingdom
3Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

PTEN Regulates VEGF, VEGFR1 Expression and Its Clinical Significance in Myeloid Leukemia

Zhiyong Cheng*, Lin Pan, MD*, Xiaoling Guo*, Xuejun Zhang* and Fuxu Wang*

Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, China

Overexpression of BAALC and MN1 Predict Worse Outcome in De Novo AML with Partial Tandem Duplication of MLL

Tung-Liang Lin1*, Lee-Yung Shih2, Der-Cherng Liang3, Chein-Fuang Huang1*, Chia-Hui Chang2*, Ming-Chung Kuo1*, Chang-Liang Lai2* and Tung-Huei Lin2*

1Chang Gung Memorial Hospital, Taipei, Taiwan
2Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan
3Mackay Memorial Hospital, Taipei, Taiwan

Prognostic Value of Monosomal Karyotype in Patients with Primary Acute Myeloid Leukemia On Behalf of Spanish CETLAM Group

Isabel Granada1*, Salut Brunet2*, Montserrat Hoyos2*, Dolors Costa3*, Anna Aventín2*, Isabel Marugán4*, Teresa Vallespí5*, Marta Barnues6*, JJ Duarte7*, Francesc Solé8*, Montserrat Teixidó9*, M. Mascaró10*, Andreu Llorente11*, Ramon Guardia12*, Mar Tormo13*, Rafael F. Duarte14*, Fuensanta Millá1*, Jordi Esteve3*, Josep-Maria Ribera, MD, PhD15 and Jordi Sierra2*

1Institut Català d'Oncologia., CETLAM Group, Badalona, Spain
2Hospital de la Santa Creu i Sant Pau., CETLAM Group, Barcelona, Spain
3Hospital Clínic., CETLAM Group, Barcelona, Spain
4Hospital Clínico Universitario, CETLAM Group, Valencia, Spain
5Hospital Universitario Vall d'Hebrón, CETLAM Group, Barcelona, Spain
6Hospital Sont Llatzer, CETLAM Group, Mallorca, Spain
7CETLAM Group, Málaga, Spain
8Hospital del Mar, CETLAM Group, Barcelona, Spain
9Hospital Arnau de Vilanova, CETLAM Group, Lleida, Spain
10Hospital Son Dureta, CETLAM Group, Palma de Mallorca, Spain
11Hospital Joan XXIII, CETLAM Group, Tarragona, Spain
12Institut Català d'Oncologia., CETLAM Group, Girona, Spain
13Hematology, Hospital Clinico Universitario, Valencia, Spain
14Institut Català d'Oncologia., CETLAM Group, Hospitalet, Spain
15Clinical Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

Osteopontin - A New Angiogenic Factor Which Correlates with Circulating Endothelial Cells in Acute Myeloid Leukemia

Agnieszka Wierzbowska*, Magdalena Czemerska*, Anna Krawczyńska*, Agnieszka Pluta*, Anna Szmigielska*, Anna Wolska* and Tadeusz Robak

Department of Hematology, Medical University of Lodz, Lodz, Poland

A Stable and Reproducible Xenotransplant Model for AML

Muriel Malaise, PhD1*, Konstanze Doehner, MD2*, Dirk Reinhardt, MD, PhD3, Klaus-Michael Debatin, MD4 and Selim Corbacioglu, MD1

1Pediatrics, University of Ulm, Ulm, Germany
2Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
3AML BFM study group, Hannover Medical School, Hannover, Germany
4Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany

The Downregulation of Onzin Expression and Its Potential Role through Physical and Functional Interaction with PU.1 in AML Cell Differentiation

Ying Huang1* and Shao-Fang Wu2*

1Department of Pathophysiology, Shanghai Jiaotong University School of Medicine, Shanghai, China
2Institute of Health Sciences, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences-SJTU-SM, Shanghai, China

MicroRNA Expression Contributes to Hypoxia-Inducible Factor-1a-Induced Differentiation of Myeloid Leukemic Cells

Ming He1*, Bo Zhang2*, Qianqian Yin2*, Meng Guo2*, Qian Zhao1* and Guo-Qiang Chen3

1Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Institute of Medical Science of Shanghai Jiaotong University, Shanghai, China
2Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, SJTU-SM, Shanghai 200025, China, Shanghai, China

Genomic Copy Number Alterations and Clustering Analysis Using Array CGH in Acute Myeloid Leukemia with Normal Karyotype

Kyung Ran Jun, MD1*, Eul-Ju Seo, MD1*, Seo-Jin Park, MD1*, Seongsoo Jang, MD1, Chan-Jeoung Park, MD1, Hyun-Sook Chi, M.D.1, Jung-Hee Lee, MD2*, Je-Hwan Lee, MD2 and Kyoo Hyung Lee, MD2

1Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
2Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Expressions of G-CSF Receptor in Tumor Cells Might Stimulate the Proliferation of Malignant Cells Upon Treatment of G-CSF

Tae Young Kim1*, Hee Won Moon2*, Bora Oh3*, Sang Mee Hwang4*, Ja-Lok Ku5* and Dong Soon Lee6*

1Department Molecular and clinical oncology, Seoul National University College of Medicine, Seoul, South Korea
2Department of Laboratory Medicine, Konkuk University College of Medicine, Seoul, South Korea
3Department of Molecular and Clinical Oncology, Seoul National University College of Medicine, Seoul
4Seoul National University College of Medicine, Seoul, South Korea
5Korean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University, Seoul, South Korea
6Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, South Korea

Invasive Aspergillosis: A New Important Risk Factor On Short and Long-Term Survival of AML Patients

Mauricette Michallet, MD, PhD1, Thomas Bénet2*, Samira Kraghel1*, Mohamad Sobh, Pharm.M1*, Mohamed El Hamri, PhD1*, Giovanna Cannas, MD1*, Franck Emmanuel Nicolini, MD, PhD1*, Emmanuelle Nicolas-Virelizier, MD1*, Hélène Labussière, MD1*, Sophie Ducastelle, MD1*, Roberto Crocchiolo, MD1*, Fiorenza Barraco, MD1*, Xavier Thomas, MD, PhD1*, Youcef Chelghoum, MD1*, Marie-Christine Nicoll2*, Anne-Lise Bienvenu3*, Florence Persat3*, Frédérique De Monbrison3*, Najeeb Fanari, MD1*, Samia Madene, MD1* and Philippe Vanhems, MD2*

1Hematology, Edouard Herriot Hospital, Lyon, France
2Laboratoire d'Hygiène, Edouard Herriot Hospital, Lyon, France
3Laboratoire de Parasitologie et de Mycologie Médicale, Edouard Herriot Hospital, Lyon

The Use of Purine Analogues Does Not Aggravate Infectious Complications During Induction and Consolidation Therapy of Acute Myeloid Leukemia

Marek Seweryn*, Jerzy Wojnar*, Dariusz Kata* and Slawomira Kyrcz-Krzemien*

Dept. of Hematology and BMT, Silesian Medical University Hospital SPSKM, Katowice, Poland

Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML)

Anna K Brady, BS, BA1*, Alex Z Fu, PhD2*, Marc Earl, PharmD3*, Matt Kalaycio4, Anjali Advani, MD5, Yogen Saunthararajah, M.D.6, Ronald Sobecks4, Edward Copelan, MD4 and Mikkael A. Sekeres, MD, MS7

1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
3Pediatric Hematology-Oncology, The Cleveland Clinic, Cleveland,, OH
4Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
6Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
7Hematologic Oncology and Blood Disorders R35, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

Gloria Mattiuzzi, MD1, Amit Lahoti2*, Abdulla Salahudeen2*, Farhad Ravandi, M.D.1*, Jorge Cortes, MD1, Khanh Vu, MD3* and Hagop Kantarjian, MD1

1Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
2General Internal Medicine, AT & EC, U.T. M.D. Anderson Cancer Center, Houston, TX
3Leukemia/General Internal Medicine, AT & EC, U.T. M.D. Anderson Cancer Center, Houston, TX

Tumor-Forming Leukemia in Breast and Ovary

Isabel Cunningham, MD

Hematology/Oncology, Columbia University College of Physicians and Surgeons, New York, NY

Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported

Ash A Alizadeh, MD, PhD1, James S. McClellan, MD, PhD2, Jason R. Gotlib, MD3*, Steven Coutre, MD4, Ravindra Majeti, MD, PhD5, Holbrook E Kohrt, MD1 and Bruno C. Medeiros, MD6

1Department of Medicine, Division of Hematology, Stanford University, Stanford, CA
2Department of Medicine, Divisions of Hematology and Oncology, Stanford University, Stanford, CA
3Department of Medicine, Division of Hematology, Stanford Cancer Center, Stanford Univ., Stanford, CA
4Department of Medicine, Division of Hematology, Stanford Univ. School of Med., Stanford, CA
5Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Palo Alto, CA
6Department of Medicine, Division of Hematology, Stanford Cancer Center, Stanford University, Stanford, CA

Therapy-Related PML-RARα Leukemia: An Emerging Disease. Report of 10 Cases From One Department of Hematology

Maida Navarrete, MD*, Teresa Vallespi, MD, PhD, Anny Jaramillo, MD*, Carmen Sánchez-Morata, MD*, Carlos Palacio, MD*, Noemí Martínez-Morgado*, Ángel Guerra-Moreno*, Margarita Ortega, PhD* and Javier Bueno, MD*

Hematology, Hospital Universitario Vall d'Hebron, Barcelona, Spain

*signifies non-member of ASH